FTC Blocks Edwards Lifesciences' JenaValve Acquisition; Company Raises Full-Year EPS Guidance
Summary
Edwards Lifesciences' planned acquisition of JenaValve Technology has been blocked by the FTC, leading the company to withdraw from the deal while simultaneously raising its full-year 2026 adjusted EPS guidance.
Key Events
-
Acquisition Blocked by FTC
The U.S. District Court for the District of Columbia granted the FTC's motion for an injunction, preventing Edwards Lifesciences from acquiring JenaValve Technology, Inc.
-
Full-Year EPS Guidance Raised
Edwards Lifesciences revised its full-year 2026 adjusted EPS guidance to $2.90 – $3.05, an increase from the earlier guidance of $2.80 – $2.95, despite the blocked acquisition.
Analysis
The U.S. Federal Trade Commission (FTC) has successfully blocked Edwards Lifesciences' proposed acquisition of JenaValve Technology, Inc., preventing the company from expanding its structural heart portfolio through this specific deal. While Edwards Lifesciences expressed disagreement with the decision, believing the acquisition was in the best interest of patients, the company simultaneously revised its full-year 2026 adjusted EPS guidance upwards. This suggests that despite the strategic setback, the company anticipates stronger financial performance from its existing operations. The market may view the blocked acquisition as removing potential integration risks or capital deployment, especially as the stock is currently trading near its 52-week high, indicating strong underlying performance.
At the time of this filing, EW was trading at $85.13 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $49.1B. The 52-week trading range was $65.94 to $87.89. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.